The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study of TPST-1120 as a single agent and in combination with nivolumab in subjects with advanced solid tumors.
 
Mark Yarchoan
Consulting or Advisory Role - AstraZeneca; Eisai; Exelixis; Genentech/Roche; Hepion Pharmaceuticals; Replimune
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Incyte (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - Merck
 
John D. Powderly
Employment - BioCytics; Carolina BioOncology Institute
Leadership - BioCytics; Carolina BioOncology Institute
Stock and Other Ownership Interests - BioCytics; Carolina BioOncology Institute
Consulting or Advisory Role - Aavocyte; Abbvie; AstraZeneca/MedImmune; Boxer Capital; Genentech/Roche; Phanes Therapeutics; TERUMO; TopAlliance BioSciences Inc
Research Funding - Abbvie; Adagene (Inst); Alkermes; Apros Therapeutics; Arcus Biosciences; Ascendis Pharma (Inst); AstraZeneca/MedImmune; Atreca (Inst); BioBank Online (Inst); BJ Bioscience (Inst); Bristol-Myers Squibb; Calico; CEM Corporation (Inst); Conjupro Biotherapeutics (Inst); Corvus Pharmaceuticals; Cullinan Oncology (Inst); Curis; EMD Serono; Engineered BioPharmaceuticals (Inst); Fate Therapeutics (Inst); FLX Bio; Function Oncology (Inst); Genentech/Roche; I-Mab (Inst); Immune-Onc Therapeutics (Inst); Incyte; Jounce Therapeutics; Lilly/ImClone; Macrogenics; Merck (Inst); Molecular Templates (Inst); MT Group (Inst); NextCure (Inst); Nuvation Bio (Inst); Pioma Chemicals (Inst); Precision for Medicine (Inst); Repertoire Immune Medicines (Inst); Replimune (Inst); Seagen; Sequenom (Inst); STEMCELL Technologies (Inst); Tempest Therapeutics; Therapeutic BrainPower LLC (Inst); Top Alliance BioScience; Trethera (Inst); Xilio Therapeutics (Inst); Xilis (Inst); Zenshine (Inst)
Patents, Royalties, Other Intellectual Property - BioCytics is developing intellectual property for cellular immunotherapy
 
Bruno R. Bastos
Consulting or Advisory Role - AstraZeneca; Bayer; Dendreon; Genzyme; Regeneron
Speakers' Bureau - Sanofi/Regeneron; Seattle Genetics/Astellas
Research Funding - Actuate Therapeutics (Inst); Altor BioScience (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Nektar (Inst); Tempest Therapeutics (Inst); Tolero Pharmaceuticals (Inst); US Oncology (Inst)
 
Thomas Benjamin Karasic
Honoraria - AstraZeneca/MedImmune; Exelixis; Incyte; Ipsen; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); H3 Biomedicine (Inst); Lilly (Inst); Sirtex Medical (Inst); Syndax (Inst); Taiho Pharmaceutical (Inst); Tempest Therapeutics (Inst); Xencor (Inst)
 
Oxana V. Crysler
Research Funding - ACCRU (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst); tempes (Inst)
 
Pamela N. Munster
Leadership - Alessa Therapeutics; EpiAxis Therapeutics
Stock and Other Ownership Interests - Alessa Therapeutics; AtlasMedx; OnKure
Honoraria - Alkermes; AstraZeneca/Merck; Athenex; GlaxoSmithKline; Olema Pharmaceuticals
Consulting or Advisory Role - Alessa Therapeutics; AtlasMedx; BeiGene; Olema Pharmaceuticals; RasCal
Research Funding - Actuate Therapeutics (Inst); Amgen (Inst); Arch Oncology (Inst); Arvinas (Inst); Bliss Biopharmaceutical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Cyteir; Deciphera (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Immune Design (Inst); Merck (Inst); Novartis (Inst); oncosec (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Sanofi (Inst); Tempest Therapeutics (Inst); Tesaro/GSK (Inst); Xynomic Pharma (Inst)
Patents, Royalties, Other Intellectual Property - UCSF patent on using silastic implants to deliver anticancer agents
 
Meredith McKean
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Castle Biosciences (Inst); Eisai (Inst); IDEAYA Biosciences (Inst); ITeos Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst)
Research Funding - Alpine Immune Sciences (Inst); Arcus Biosciences (Inst); Arvinas (Inst); Ascentage Pharma Group (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioMed Valley Discoveries (Inst); BioNTech (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Foghorn Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Immvira (Inst); Infinity Pharmaceuticals (Inst); Jacobio (Inst); Kechow Pharma (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); MedImmune (Inst); Mereo BioPharma (Inst); Metabomed (Inst); Moderna Therapeutics (Inst); NBE Therapeutics (Inst); Nektar (Inst); Novartis (Inst); Oncorus (Inst); PACT Pharma (Inst); Pfizer (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Pyramid Biosciences (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Scholar Rock (Inst); Seagen (Inst); Synthorx (Inst); Takeda (Inst); Tempest Therapeutics (Inst); TeneoBio (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Top Alliance BioScience (Inst); Xilio Therapeutics (Inst)
 
Leisha A. Emens
Leadership - Society for Immunotherapy of Cancer; Society for Immunotherapy of Cancer
Stock and Other Ownership Interests - Molecuvax
Consulting or Advisory Role - Abbvie; Bristol Meyers Squibb; Chugai Pharma; CytomX Therapeutics; DNAMx; Genentech/Roche; Gilead Sciences; GPCR Therapeutics; Immune-Onc Therapeutics; Immunitas; Lilly; Macrogenics; Molecuvax; Replimune; Shionogi; Silverback Therapeutics
Research Funding - Abbvie; Aduro Biotech; AstraZeneca; Bolt Biotherapeutics; Bristol Myers Squibb; Compugen; Corvus Pharmaceuticals; CytomX Therapeutics; EMD Serono; Genentech; Immune-Onc Therapeutics; Maxcyte; Merck; NextCure; Roche; Silverback Therapeutics; Takeda; Tempest Therapeutics
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech; Roche
Other Relationship - Aduro Biotech
 
Yvonne M. Saenger
Research Funding - Regeneron
 
Yasser Ged
Consulting or Advisory Role - AVEO; Bristol Myers Squibb; Exelixis
 
Robert Stagg
Employment - Tempest Therapeutics
Stock and Other Ownership Interests - Tempest Therapeutics
 
Andreas Goutopoulos
Consulting or Advisory Role - Loxo; Syndax; Various
Patents, Royalties, Other Intellectual Property - Various patents and applications
 
Anne Moon
Employment - Tempest Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb; Chinook Therapeutics; Cytokinetics; Johnson & Johnson; Merck; Pfizer; Tempest Therapeutics
 
Yonchu Jenkins
Employment - Abalone Biosciences (I); Calithera Biosciences; Second Genome (I); Tempest Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb (I); Johnson & Johnson/Janssen (I); Novartis (I); Seagen (I); Vertex (I)
Consulting or Advisory Role - Calithera Biosciences; Xoma (I)
 
Peppi Prasit
Employment - Tempest Therapeutics
Leadership - AM Sciences; Genesis Therapeutics; Tempest Therapeutics
Stock and Other Ownership Interests - AM Sciences; Genesis therapeutics; Tempest Therapeutics
Honoraria - Genesis Therapeutics; Glycosyn; Shouti; Tempest Therapeutics
Consulting or Advisory Role - Genesis Therapeutics; Glycosyn; Shouti; Tempest Therapeutics
Patents, Royalties, Other Intellectual Property - Inception Sciences; Tempest Therapeutics
 
Thomas Walter Dubensky
Employment - Tempest Therapeutics
Leadership - Tempest Therapeutics
Stock and Other Ownership Interests - Tempest Therapeutics; Tempest Therapeutics; Tempest Therapeutics; Tempest Therapeutics
Consulting or Advisory Role - Avidea Technologies; Oncorus
Patents, Royalties, Other Intellectual Property - Multiple issued (ca. 40) and pending patents, all of which have been assigned to the various companies which own the rights to them (e.g., Novartis, Chinook, Tempest). I receive no royalties from any of these patents.
 
Sam H. Whiting
Employment - Calithera Biosciences; Recludix Pharma (I); Seagen (I); Tempest Therapeutics
Leadership - Recludix Pharma (I); Tempest Therapeutics
Stock and Other Ownership Interests - Recludix Pharma (I); Tempest Therapeutics
 
Susanna Varkey Ulahannan
Consulting or Advisory Role - Array BioPharma; Bayer; Eisai; Incyte; Syros Pharmaceuticals
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); ArQule (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); atreca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CicloMed (Inst); Erasca, Inc (Inst); evelo biosciences (Inst); Exelixis (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); IgM Biosciences (Inst); Incyte (Inst); Klus Pharma (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Synermore biologics (Inst); Takeda (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tempest Therapeutics (Inst); Tesaro (Inst); Vigeo Therapeutics (Inst)